HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shana R Dalton Selected Research

ralpancizumab

9/2022Regulatory Experience Assessing the Carcinogenic Potential of a Monoclonal Antibody Inhibiting PCSK9, Bococizumab, Including a 2-Year Carcinogenicity Study in Rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shana R Dalton Research Topics

Disease

1Hypercholesterolemia
09/2022
1Neoplasms (Cancer)
09/2022
1Inflammation (Inflammations)
04/2009
1Necrosis
04/2009
1Fibrosis (Cirrhosis)
04/2007

Drug/Important Bio-Agent (IBA)

1bococizumabIBA
09/2022
1ralpancizumabIBA
09/2022
1Monoclonal AntibodiesIBA
09/2022
1Ethanol (Ethyl Alcohol)IBA
04/2009
1Fibrillar CollagensIBA
04/2007